GlassScriptPhysician profile
Duff A Rardin
NPI 1114989324
$481.68
in general payments reported to CMS, 2019-2025
10 companies · $17.35 in 2025
The $17.35 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $139 · 2020: $59.52 · 2021: $88.67 · 2022: $11.84 · 2024: $165 · 2025: $17.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $182.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $164.92 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Alexion Pharmaceuticals, INC. | $83.40 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $59.52 | 2020 | |
| Novartis Pharmaceuticals Corporation | $53.08 | 2019-2022 | |
| Allergan, INC. | $28.64 | 2021 | |
| Biogen, INC. | $23.19 | 2021 | |
| Emd Serono, INC. | $18.42 | 2019 | |
| Aucta Pharmaceuticals, INC. | $17.35 | 2025 | Motpoly Xr |
| Lilly USA, LLC | $17.10 | 2019 | |
| Abbvie INC. | $16.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Duff Rardin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.